Migle Kazlauskiene

Binding affinity in drug design: experimental and computational techniques

Lina Baranauskienė, V. Kairys, D. Matulis, 2019, Expert opinion on drug discovery.

Type III-A CRISPR-associated protein Csm6 degrades cyclic hexa-adenylate activator using both CARF and HEPN domains

V. Šikšnys, G. Tamulaitis, Dalia Smalakyte, 2020, Nucleic acids research.

Spatiotemporal Control of Type III-A CRISPR-Cas Immunity: Coupling DNA Degradation with the Target RNA Recognition.

Česlovas Venclovas, Gintautas Tamulaitis, Virginijus Siksnys, 2016, Molecular cell.

A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems

Česlovas Venclovas, Gintautas Tamulaitis, Virginijus Siksnys, 2017, Science.

Hakai is required for stabilization of core components of the m6A mRNA methylation machinery

M. Jinek, Jean-Yves Roignant, M. Helm, 2021, Nature Communications.

Programmable RNA shredding by the type III-A CRISPR-Cas system of Streptococcus thermophilus.

Ceslovas Venclovas, Philippe Horvath, Gintautas Tamulaitis, 2014, Molecular cell.

Genetic Dissection of the Type III-A CRISPR-Cas System Csm Complex Reveals Roles of Individual Subunits.

V. Šikšnys, G. Tamulaitis, G. Tamulaitienė, 2019, Cell reports.

Recent advances in computational and experimental protein-ligand affinity determination techniques

V. Kairys, D. Matulis, V. Petrauskas, 2024, Expert Opinion on Drug Discovery.